Siglec receptors as new immune checkpoints in cancer

Elsevier

Available online 7 August 2022, 101112

Molecular Aspects of MedicineAbstract

Cancer immunotherapy in the form of immune checkpoint inhibitors and cellular therapies has improved the treatment and prognosis of many patients. Nevertheless, most cancers are still resistant to currently approved cancer immunotherapies. New approaches and rational combinations are needed to overcome these resistances. There is emerging evidence that Siglec receptors could be regarded as new immune checkpoints and targets for cancer immunotherapy. In this review, we summarize the experimental evidence supporting Siglec receptors as new immune checkpoints in cancer and discuss their mechanisms of action, as well as current efforts to target Siglec receptors and their interactions with sialoglycan Siglec-ligands.

Keywords

Cancer immunotherapy

T cells

Immune checkpoint inhibitor

Monoclonal antibodies

Sialidase

Sialic acid

Innate immunity

© 2022 The Authors. Published by Elsevier Ltd.

留言 (0)

沒有登入
gif